VLP Therapeutics

Develops VLP (virus-like particle) and replicon (self-amplifying RNA) vaccines and cancer immunotherapies targeting infectious diseases such as malaria, dengue, COVID-19 and influenza, and cancer, where existing prevention and treatment options are limited. Serves population-level health needs through healthcare systems, government agencies and research collaborators that fund, trial and deploy vaccines. Delivers via in-house research and development and investigational drug manufacturing at its Fukuoka site, advancing candidates through clinical trials.

Key features

• VLP (virus-like particle) vaccine platform
• Replicon self-amplifying RNA platform
• T-cell inducing universal COVID vaccine
• 5-methylcytidine modified replicon technology
• IL-12 expressing viral replicon particles
• Investigational drug manufacturing in Fukuoka
• Phase 1 to Phase 3 clinical trials
• Cancer immunotherapy research and development